CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
CASI Pharmaceuticals reported a 60% year-over-year drop in Q3 revenue, primarily due to estimated goods returns for EVOMELA, leading to a widened net loss of $10.9 million. The company is appealing Nasdaq's delisting determination and plans to divest its China business by Q2 2026. CASI will present CID-103 study results at ASH 2025 and is advancing trials in the U.S. and China. Wall Street's median 12-month price target for CASI is $4.00, significantly above its current price.
)
Overview
- CASI Q3 revenue falls 60% yr/yr due to estimated goods returns for EVOMELA
- Net loss for Q3 2025 increased to $10.9 mln from $8.4 mln last year
- Company appeals Nasdaq delisting determination, seeking extension to regain compliance
Outlook
- CASI plans to complete China business divestiture by Q2 2026
- Company to present CID-103 study results at ASH 2025 on Dec 7
- CASI advancing CID-103 trials in U.S. and China
Result Drivers
- REVENUE DECLINE - Revenue fell 60% yr/yr due to estimated goods returns for EVOMELA, which also impacted net loss
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 $3.08
Revenue mln
Analyst Coverage
- The one available analyst rating on the shares is “buy”
- The average consensus recommendation for the pharmaceuticals peer group is “buy”
- Wall Street’s median 12-month price target for CASI Pharmaceuticals Inc is $4.00, about 66.6% above its November 13 closing price of $1.34
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
